10-Q: Scientific Industries Q3 2025: Genie Sale Boosts Income

Scientific Industries reports a significant net income for Q3 2025 driven by the sale of its Genie product line, despite ongoing operational losses in continuing segments.

Summary

• Net income for the three months ended September 30, 2025, was $3,994,400, a substantial improvement from a net loss of $1,180,100 in the prior year period.
• Net income for the nine months ended September 30, 2025, was $692,200, compared to a net loss of $4,515,400 in the prior year period.
• The primary driver for the positive net income was a $5,263,400 gain on the disposition of the Genie Product Line in August 2025.
• Revenue from continuing operations for the three months ended September 30, 2025, increased by 5.2% to $1,404,000, primarily due to increased sales in the Torbal division.
• Revenue from continuing operations for the nine months ended September 30, 2025, decreased by 2.5% to $3,427,100, mainly due to a $441,200 decrease in Bioprocessing Systems Operations revenue.
• Gross profit percentage for continuing operations decreased to 45.5% for the three months and 39.8% for the nine months ended September 30, 2025, compared to 51.0% and 44.1% respectively in the prior year periods.
• The company continues to generate negative cash flows from continuing operations, with $4,390,700 used in operating activities for the nine months ended September 30, 2025.
• Cash and cash equivalents increased to $1,162,600 as of September 30, 2025, from $587,900 at December 31, 2024, largely due to proceeds from the Genie sale and equity financing.
• The company raised $1,952,300 from financing activities for the nine months ended September 30, 2025, through common stock issuance and warrant exercises.

Sentiment

Score: 6

Explanation: The significant one-time gain from the asset sale dramatically improved net income and cash position, providing a temporary boost to liquidity. However, underlying continuing operations still show losses and negative cash flow, and the Bioprocessing segment faces market softness and delays. The capital raise also helps liquidity but dilutes existing shareholders. The overall sentiment is cautiously positive due to the immediate financial relief, but long-term operational profitability remains a concern.

Positives

• Significant net income of $3,994,400 for the three months and $692,200 for the nine months ended September 30, 2025, primarily due to the $5,263,400 gain on the sale of the Genie Product Line.
• Increased cash and cash equivalents to $1,162,600 as of September 30, 2025.
• Net cash provided by investing activities was $2,444,300 for the nine months ended September 30, 2025, reflecting the Genie division asset sale proceeds.
• Torbal division sales increased by $186,400 for the three months and $353,700 for the nine months ended September 30, 2025, driven by VIVID automated pill counters.
• Reduced operating expenses for continuing operations for the three months ended September 30, 2025, compared to the prior year.
• Reduced General and Administrative expenses by $306,800 (10.7%) for the nine months ended September 30, 2025.
• Reduced Selling expenses by $57,700 (2.4%) for the nine months ended September 30, 2025.
• Reduced Research and Development expenses by $75,100 (3.9%) for the nine months ended September 30, 2025.

Negatives

• Bioprocessing Systems Operations revenues decreased by $141,700 for the three months and $441,200 for the nine months ended September 30, 2025, due to market softness and customer delays.
• Gross profit percentage for continuing operations declined to 45.5% (Q3 2025) from 51.0% (Q3 2024) and to 39.8% (9M 2025) from 44.1% (9M 2024), partly due to fixed costs on lower Bioprocessing sales and increased material costs for Torbal OEM products.
• Continuing operations still generated a loss of $1,522,300 for the three months and $5,434,700 for the nine months ended September 30, 2025, before income tax expense.
• Net cash used in continuing operating activities increased to $4,390,700 for the nine months ended September 30, 2025, from $4,186,000 in the prior year period.
• The company has an accumulated deficit of $33,238,300 as of September 30, 2025, and expects to continue generating negative cash flows from operations in the foreseeable future.

Risks

• No assurance that management's current operating plan will be successful in addressing negative cash flows from operations.
• Product demand, market acceptance, success of marketing strategy, and success of expansion efforts.
• Impact of competition and adverse economic conditions.
• Factors affecting the company's business that are beyond its control.
• The company maintains a full valuation allowance of $10,559,600 against its consolidated net deferred tax asset, indicating uncertainty about future taxable income.

Future Outlook

The company expects to continue generating negative cash flows from operations in the foreseeable future but believes its cash on hand, including investments and incoming cash from post-sale agreements, is sufficient to fund operations for at least one year from the issuance date of the financial statements. However, there is no assurance that management's current operating plan will be successful.

Management Comments

• The Company expects that with the cash generated from the recent division sale plus other incoming cash related to the various post sale agreements is sufficient for at least one year from the date of issuance of the consolidated financial statements for the nine months ended September 30, 2025.
• However, there is no assurance that management's current operating plan will be successful.

Industry Context

The Bioprocessing Systems Operations experienced "overall softness in the market" and "customer delays," suggesting a challenging environment for this segment, potentially reflecting broader industry trends or specific competitive pressures. The Torbal division's growth, particularly with VIVID automated pill counters, indicates strength in specific niche areas of laboratory equipment.

Management Changes

Corporate Governance

Related Party Transactions

• Paid $24,000 to Mr. John Nicols (a Director) for consulting services to the Bioprocessing Systems segment during the three months ended September 30, 2025.
• Paid $72,000 to Mr. John Nicols (a Director) for consulting services to the Bioprocessing Systems segment during the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Benefited from the significant one-time gain from the Genie sale, which improved net income and reduced the accumulated deficit. However, new equity issuances caused dilution.
• Employees: Some employees participated in a voluntary Salary/Compensation Waiver Program in exchange for stock options, potentially impacting immediate cash compensation but offering long-term equity incentives.
• Customers (Genie Division): The sale of the Genie Division means a change in supplier for products previously offered by Scientific Industries, though the company will continue to supply products under an MSA for a transition period.
• Customers (Torbal Division): Benefited from increased sales, particularly of VIVID automated pill counters.
• Customers (Bioprocessing Systems): Experienced delays in orders and product availability, indicating potential dissatisfaction or missed opportunities.

Next Steps

• Supply products to Troemner, LLC under a Manufacturing and Supply Agreement for at least six months, renewable for 3-month periods up to a total of twelve months.
• Provide transition services, including training and transfer of know-how, to Troemner, LLC.
• Continue to evaluate the impact of adopting new accounting standards ASU 2023-09, ASU 2024-03, and ASU 2025-01 on disclosures.

Key Dates

Recommendation

The significant one-time gain from the Genie product line sale has provided a much-needed boost to net income and liquidity, reducing the accumulated deficit and improving the cash position. This provides a temporary reprieve and allows the company to focus on its continuing operations. However, the underlying Bioprocessing Systems segment continues to face market softness, customer delays, and contributes to ongoing operational losses and negative cash flow from continuing operations. While the capital raise has improved short-term financial flexibility, the long-term profitability of the core business remains unproven. Investors should hold to observe if the company can leverage the proceeds from the asset sale to achieve sustainable profitability in its remaining segments and address the persistent operational challenges.

Keywords

Laboratory equipment, Bioprocessing, Financial results, SEC filing, 10-Q, Asset sale, Genie product line, Torbal, VIVID pill counters, Equity financing, Cash flow, Operating loss, Revenue, Gross profit, Scientific Industries